Optomechanical characterization of acoustic modes in a mirror

We present an experimental study of the internal mechanical vibration modes of a mirror. We determine the frequency repartition of acoustic resonances via a spectral analysis of the Brownian motion of the mirror, and the spatial profile of the acoustic modes by monitoring their mechanical response to a resonant radiation pressure force swept across the mirror surface. We have applied this technique to mirrors with cylindrical and plano-convex geometries, and compared the experimental results to theoretical predictions. We have in particular observed the gaussian modes predicted for plano-convex mirrors.Comment: 8 pages, 8 figures, RevTe

Continuous variable entanglement by radiation pressure

We show that the radiation pressure of an intense optical field impinging on a perfectly reflecting vibrating mirror is able to entangle in a robust way the first two optical sideband modes. Under appropriate conditions, the generated entangled state is of EPR type [A. Einstein, {\it et al.}, Phys. Rev. {\bf 47}, 777 (1935)].Comment: 11 pages, 3 figure

Quantum noise in second generation, signal-recycled laser interferometric gravitational-wave detectors

It has long been thought that the sensitivity of laser interferometric gravitational-wave detectors is limited by the free-mass standard quantum limit, unless radical redesigns of the interferometers or modifications of their input/output optics are introduced. Within a fully quantum-mechanical approach we show that in a second-generation interferometer composed of arm cavities and a signal recycling cavity, e.g., the LIGO-II configuration, (i) quantum shot noise and quantum radiation-pressure-fluctuation noise are dynamically correlated, (ii) the noise curve exhibits two resonant dips, (iii) the Standard Quantum Limit can be beaten by a factor of 2, over a frequency range \Delta f/f \sim 1, but at the price of increasing noise at lower frequencies.Comment: 35 pages, 9 figures; few misprints corrected and some references adde

Quantum noise in the position measurement of a cavity mirror undergoing Brownian motion

We perform a quantum theoretical calculation of the noise power spectrum for a phase measurement of the light output from a coherently driven optical cavity with a freely moving rear mirror. We examine how the noise resulting from the quantum back action appears among the various contributions from other noise sources. We do not assume an ideal (homodyne) phase measurement, but rather consider phase modulation detection, which we show has a different shot noise level. We also take into account the effects of thermal damping of the mirror, losses within the cavity, and classical laser noise. We relate our theoretical results to experimental parameters, so as to make direct comparisons with current experiments simple. We also show that in this situation, the standard Brownian motion master equation is inadequate for describing the thermal damping of the mirror, as it produces a spurious term in the steady-state phase fluctuation spectrum. The corrected Brownian motion master equation [L. Diosi, Europhys. Lett. {\bf 22}, 1 (1993)] rectifies this inadequacy.Comment: 12 pages revtex, 2 figure

Preparation of nonclassical states in cavities with a moving mirror

Published versio

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial

IMPORTANCE: Secretory phospholipase A2(sPLA2) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA2inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown. OBJECTIVE: To determine the effects of sPLA2inhibition with varespladib on cardiovascular outcomes. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized, multicenter trial at 362 academic and community hospitals in Europe, Australia, New Zealand, India, and North America of 5145 patients randomized within 96 hours of presentation of an acute coronary syndrome (ACS) to either varespladib (n = 2572) or placebo (n = 2573) with enrollment between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012). INTERVENTIONS: Participants were randomized to receive varespladib (500 mg) or placebo daily for 16 weeks, in addition to atorvastatin and other established therapies. MAIN OUTCOMES AND MEASURES: The primary efficacy measurewas a composite of cardiovascular mortality, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Six-month survival status was also evaluated. RESULTS: At a prespecified interim analysis, including 212 primary end point events, the independent data and safety monitoring board recommended termination of the trial for futility and possible harm. The primary end point occurred in 136 patients (6.1%) treated with varespladib compared with 109 patients (5.1%) treated with placebo (hazard ratio [HR], 1.25; 95%CI, 0.97-1.61; log-rank P = .08). Varespladib was associated with a greater risk of MI (78 [3.4%] vs 47 [2.2%]; HR, 1.66; 95%CI, 1.16-2.39; log-rank P = .005). The composite secondary end point of cardiovascular mortality, MI, and stroke was observed in 107 patients (4.6%) in the varespladib group and 79 patients (3.8%) in the placebo group (HR, 1.36; 95% CI, 1.02-1.82; P = .04). CONCLUSIONS AND RELEVANCE: In patients with recent ACS, varespladib did not reduce the risk of recurrent cardiovascular events and significantly increased the risk of MI. The sPLA2inhibition with varespladib may be harmful and is not a useful strategy to reduce adverse cardiovascular outcomes after ACS. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01130246. Copyright 2014 American Medical Association. All rights reserved

Strong vacuum squeezing from bichromatically driven Kerrlike cavities: from optomechanics to superconducting circuits

Squeezed light, displaying less fluctuation than vacuum in some observable, is key in the flourishing field of quantum technologies. Optical or microwave cavities containing a Kerr nonlinearity are known to potentially yield large levels of squeezing, which have been recently observed in optomechanics and nonlinear superconducting circuit platforms. Such Kerr-cavity squeezing however suffers from two fundamental drawbacks. First, optimal squeezing requires working close to turning points of a bistable cycle, which are highly unstable against noise thus rendering optimal squeezing inaccessible. Second, the light field has a macroscopic coherent component corresponding to the pump, making it less versatile than the so-called squeezed vacuum, characterised by a null mean field. Here we prove analytically and numerically that the bichromatic pumping of optomechanical and superconducting circuit cavities removes both limitations. This finding should boost the development of a new generation of robust vacuum squeezers in the microwave and optical domains with current technology

Dynamic manipulation of mechanical resonators in the high amplitude regime through optical backaction

Cavity optomechanics enables active manipulation of mechanical resonators through backaction cooling and amplification. This ability to control mechanical motion with retarded optical forces has recently spurred a race towards realizing a mechanical resonator in its quantum ground state. Here, instead of quenching optomechanical motion, we demonstrate high amplitude operation of nanomechanical resonators by utilizing a highly efficient phonon generation process. In this regime, the nanomechanical resonators gain sufficient energy from the optical field to overcome the large energy barrier of a double well potential, leading to nanomechanical slow-down and zero frequency singularity, as predicted by early theories . Besides fundamental studies and interests in parametric amplification of small forces, optomechanical backaction is also projected to open new windows for studying discrete mechanical states, and to foster applications. Here we realize a non-volatile mechanical memory element, in which bits are written and reset via optomechanical backaction by controlling the mechanical damping across the barrier. Our study casts a new perspective on the energy dynamics in coupled mechanical resonator - cavity systems and enables novel functional devices that utilize the principles of cavity optomechanics.Comment: 22 pages, 5 figure

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

BACKGROUND: The cholesteryl ester transfer protein inhibitor evacetrapib substantially raises the high-density lipoprotein (HDL) cholesterol level, reduces the low-density lipoprotein (LDL) cholesterol level, and enhances cellular cholesterol efflux capacity. We sought to determine the effect of evacetrapib on major adverse cardiovascular outcomes in patients with high-risk vascular disease. METHODS: In a multicenter, randomized, double-blind, placebo-controlled phase 3 trial, we enrolled 12,092 patients who had at least one of the following conditions: an acute coronary syndrome within the previous 30 to 365 days, cerebrovascular atherosclerotic disease, peripheral vascular arterial disease, or diabetes mellitus with coronary artery disease. Patients were randomly assigned to receive either evacetrapib at a dose of 130 mg or matching placebo, administered daily, in addition to standard medical therapy. The primary efficacy end point was the first occurrence of any component of the composite of death from cardiovascular causes, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina. RESULTS: At 3 months, a 31.1% decrease in the mean LDL cholesterol level was observed with evacetrapib versus a 6.0% increase with placebo, and a 133.2% increase in the mean HDL cholesterol level was seen with evacetrapib versus a 1.6% increase with placebo. After 1363 of the planned 1670 primary end-point events had occurred, the data and safety monitoring board recommended that the trial be terminated early because of a lack of efficacy. After a median of 26 months of evacetrapib or placebo, a primary end-point event occurred in 12.9% of the patients in the evacetrapib group and in 12.8% of those in the placebo group (hazard ratio, 1.01; 95% confidence interval, 0.91 to 1.11; P=0.91). CONCLUSIONS: Although the cholesteryl ester transfer protein inhibitor evacetrapib had favorable effects on established lipid biomarkers, treatment with evacetrapib did not result in a lower rate of cardiovascular events than placebo among patients with high-risk vascular disease. (Funded by Eli Lilly; ACCELERATE ClinicalTrials.gov number, NCT01687998 .)